<DOC>
	<DOC>NCT02876042</DOC>
	<brief_summary>The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).</brief_summary>
	<brief_title>BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Sign an Ethics Committee (EC) approved informed consent form for the registry. Implanted with the BAROSTIM NEO system in accordance with CEMark approved indications and contraindications for resistant hypertension within 30 days prior to enrollment. BAROSTIM THERAPY not yet chronically activated. Preimplant echocardiogram with left ventricular ejection fraction ≥ 50% within 30 days prior to implant. On stable, maximallytolerated, guidelinedirected cardiovascular medications for at least 30 days prior to enrollment. Objective evidence of heart failure according to the following criteria: Hospitalization for heart failure within 12 months prior to enrollment OR Echocardiographic evidence of diastolic dysfunction (LA Volume Index &gt;34 ml/m2 OR E/e &gt;13) within 30 days prior to enrollment OR NTproBNP &gt; 220 pg/mL or BNP &gt; 80 pg/mL (in atrial fibrillation, NTproBNP &gt; 600 Heart failure secondary to a reversible or treatable condition such as, cardiac structural valvular disease, acute myocarditis and pericardial constriction. Heart failure secondary to right ventricular failure or right ventricular myocardial infarction.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Preserved Ejection Fraction</keyword>
</DOC>